Cat Scratch Disease: Comprehensive Veterinary Reference Guide

Quick Q&A

Question: What is cat scratch disease and how do humans catch it from cats?

Answer: Cat scratch disease (CSD) is a bacterial infection caused primarily by Bartonella henselae, transmitted to humans through a scratch, bite, or lick from an infected cat, especially kittens. The bacteria are carried in flea feces (flea dirt) that gets on the cat's claws and fur; when a cat scratches, the contaminated flea dirt enters the skin. Most cases resolve on their own, but some require antibiotic treatment, and immunocompromised individuals can develop severe complications.

1. Introduction and Overview

Cat scratch disease (CSD), also known as cat scratch fever or bartonellosis, is a zoonotic infectious disease caused primarily by the Gram-negative bacterium Bartonella henselae. While the condition is typically self-limiting in immunocompetent individuals, it can produce a wide spectrum of clinical manifestations ranging from mild lymphadenopathy to life-threatening systemic disease involving the heart, eyes, brain, and kidneys [6][18]. The disease has garnered increasing attention in both human and veterinary medicine due to its global prevalence, emerging atypical presentations, and the growing recognition of Bartonella species as significant zoonotic pathogens.

The primary reservoir for B. henselae is the domestic cat (Felis catus), and the primary vector for transmission between cats is the cat flea (Ctenocephalides felis) [24]. Humans are accidental, dead-end hosts who typically acquire the infection through a scratch or bite from an infected cat, or through contact with flea feces that contaminate the cat's claws and fur. Kittens under one year of age are more likely to carry the bacteria and are therefore a higher risk source for human infection.

This comprehensive veterinary reference guide provides an exhaustive review of cat scratch disease, covering its microbiology, epidemiology, transmission dynamics, clinical manifestations in both cats and humans, diagnostic approaches, treatment protocols, prevention strategies, and emerging research. The content is designed for veterinary professionals, pet owners, and public health officials seeking a deep understanding of this important zoonosis.

2. Etiology and Microbiology

2.1 The Pathogen: Bartonella henselae

Bartonella henselae is a fastidious, facultative intracellular, Gram-negative bacillus belonging to the family Bartonellaceae. The organism is pleomorphic, appearing as small curved rods or coccobacilli in tissue sections. It requires specialized culture conditions, including enriched media (e.g., chocolate agar supplemented with 5% sheep blood) and incubation in a microaerophilic environment at 35-37 degrees Celsius with 5% carbon dioxide for prolonged periods (up to 21 days) [18]. This fastidious nature makes culture-based diagnosis challenging and often results in underdiagnosis.

The bacterium has a unique ability to invade and survive within erythrocytes and endothelial cells, a strategy that facilitates persistent bacteremia in reservoir hosts while evading immune clearance. B. henselae expresses several virulence factors, including adhesins that mediate attachment to host cells, type IV secretion systems that inject effector proteins into host cells, and lipopolysaccharides that modulate the host inflammatory response.

2.2 Other Bartonella Species Associated with CSD

While B. henselae is the primary causative agent, other Bartonella species have been implicated in CSD-like illnesses. Bartonella clarridgeiae has been identified as a secondary cause of CSD in humans, and recent research has focused on developing cross-protective vaccines targeting both B. henselae and B. clarridgeiae [33]. Bartonella quintana, the agent of trench fever, is primarily associated with human body lice but can occasionally cause CSD-like presentations. Other species including B. koehlerae and B. vinsonii subsp. berkhoffii have been identified in cats and may have zoonotic potential.

2.3 Strain Variation and Virulence

Genetic diversity among B. henselae strains influences pathogenicity and clinical presentation. Two major genogroups (Houston-1 and Marseille) have been described, with some evidence suggesting that certain strains are more associated with severe human disease. The emergence of multidrug-resistant strains remains a concern, though resistance patterns vary geographically [16].

3. Epidemiology and Global Distribution

3.1 Prevalence in Cat Populations

Cat scratch disease is a globally distributed zoonosis. Seroprevalence studies in cats demonstrate significant geographic variation, with rates ranging from 10% to 60% depending on region, climate, and management practices. A recent study from urban Korea found a seroprevalence of B. henselae immunoglobulin G of 12.4% among adults undergoing health screening, with cat ownership and flea exposure identified as significant risk factors [26].

In the United States, seroprevalence in cats is higher in warm, humid regions where flea populations thrive. The Rio Grande Valley in Texas, for example, has documented high rates of B. henselae and related zoonotic agents in fleas collected from domestic cats [4]. Similarly, studies from tropical regions such as the Klang Valley in Malaysia have identified emerging risks of flea-borne Bartonella in stray cat populations [39].

3.2 Human Incidence

The incidence of CSD in humans is difficult to determine precisely due to underreporting and the self-limiting nature of many cases. In the United States, estimates suggest approximately 12,000 outpatient cases and 500 hospitalizations occur annually, with children and adolescents most commonly affected. A recent retrospective analysis from southwestern China using metagenomic next-generation sequencing (mNGS)-confirmed cases in children found that CSD is more common than previously recognized in that region [30].

3.3 Seasonal and Demographic Patterns

CSD shows seasonal variation, with peak incidence in late summer and autumn, correlating with peak flea activity and kitten birth seasons. The disease disproportionately affects children under 15 years of age, likely due to increased likelihood of rough play with cats and kittens. Immunocompromised individuals, including organ transplant recipients, HIV/AIDS patients, and those on immunosuppressive therapies, are at highest risk for severe and disseminated disease [29][32].

3.4 Regional Considerations for Veterinary Practice

Veterinarians in different regions should be aware of local epidemiological patterns. In Australia, where flea control is a year-round necessity in many areas, CSD is a recognized but likely underdiagnosed condition. European veterinary associations, including the Federation of Veterinarians of Europe (FVE), emphasize the importance of flea control as a key public health measure. In Canada, the Canadian Veterinary Medical Association (CVMA) supports integrated parasite management strategies that include routine flea prevention for cats.

4. Transmission Dynamics

4.1 The Flea Vector: Ctenocephalides felis

The cat flea (Ctenocephalides felis) is the primary biological vector for B. henselae transmission among cats. The bacteria replicate within the flea's gut and are shed in large numbers in flea feces (flea dirt). Cats become infected when they ingest fleas during grooming or when flea dirt contaminates their claws and skin [24]. A recent comprehensive review by Brown (2026) revisited the transmission cycle, emphasizing that the flea gut provides a microenvironment that supports bacterial replication and that flea feces remain infectious for extended periods [24].

Flea control is therefore the single most important intervention for preventing CSD in both cats and humans. The American Veterinary Medical Association (AVMA) and the American Animal Hospital Association (AAHA) recommend year-round flea prevention for all cats, regardless of indoor/outdoor status, given that fleas can enter homes on clothing or through other pets.

4.2 Transmission from Cats to Humans

Humans acquire B. henselae through:

1. Cat scratches: The most common route. Flea dirt containing bacteria gets under the cat's claws during self-grooming. When the cat scratches a human, the contaminated claw introduces bacteria into the skin.

2. Cat bites: Direct inoculation of bacteria through bite wounds.

3. Licks on broken skin: Cats may transmit bacteria through licking open wounds or mucous membranes.

4. Flea bites: Direct transmission from flea bites to humans is possible but less common.

5. Needlestick injuries: Veterinary personnel can acquire infection through accidental needlesticks when drawing blood from bacteremic cats.

Kittens under 12 months of age are more likely to be bacteremic and are therefore a higher transmission risk. Stray and shelter cats also have higher infection rates due to increased flea exposure.

4.3 Blood Type and Susceptibility in Cats

Recent research has explored whether feline blood type influences susceptibility to Bartonella infection. A study by Spada et al. (2026) investigated whether the phenotype-B blood group in cats confers resistance or susceptibility to Bartonella spp. infection. The findings suggest that blood type may play a role in host-pathogen interactions, though further research is needed to clarify the mechanisms [11].

4.4 Other Potential Vectors

While the cat flea is the primary vector, B. henselae DNA has been detected in other arthropods. A fascinating study from Brazil identified B. henselae DNA in Rhodnius prolixus (a triatomine bug used in insectaries) and in domestic ducks (Cairina moschata) used as blood meal sources for these insects [9]. This finding raises questions about the potential for alternative vectors and reservoirs, though the epidemiological significance remains unclear.

5. Clinical Manifestations in Cats

5.1 Asymptomatic Bacteremia

The vast majority of cats infected with B. henselae show no clinical signs. Cats serve as the primary reservoir host, and the bacterium has evolved to establish persistent, asymptomatic bacteremia that can last for months to years. This asymptomatic carrier state is the primary reason why CSD is so difficult to control: healthy-appearing cats can transmit the infection to humans.

5.2 Feline Bartonellosis: Clinical Signs

When clinical signs do occur in cats, they are typically mild and nonspecific. Feline bartonellosis may present with:

• Fever: Intermittent or persistent pyrexia
• Lymphadenopathy: Enlarged lymph nodes, particularly in the head and neck region
• Gingivitis and stomatitis: Chronic oral inflammation has been associated with Bartonella infection
• Uveitis: Inflammation of the uveal tract of the eye
• Neurologic signs: Rarely, meningitis or encephalitis
• Endocarditis: Though uncommon, Bartonella is an important cause of culture-negative endocarditis in cats
• Myocarditis: Inflammation of the heart muscle

5.3 Co-infections and Comorbidities

Cats infected with B. henselae are often co-infected with other flea-borne pathogens, including Rickettsia typhi (murine typhus), Mycoplasma haemofelis, and other vector-borne agents [4]. Co-infections may complicate the clinical picture and influence disease severity.

5.4 Diagnosis in Cats

Diagnosing Bartonella infection in cats is challenging due to the fastidious nature of the organism. Available diagnostic modalities include:

• Blood culture: Requires specialized media (Bartonella alpha-Proteobacteria growth medium or BAPGM) and prolonged incubation (up to 3 weeks). Sensitivity is low, especially in cats with low-level bacteremia.

• Serology: Detection of antibodies against B. henselae using immunofluorescence antibody (IFA) assays or enzyme-linked immunosorbent assays (ELISA). Serology indicates exposure but cannot distinguish active infection from past exposure.

• Polymerase chain reaction (PCR): Detection of Bartonella DNA in blood, tissue, or cerebrospinal fluid. PCR is more sensitive than culture and can be performed on various sample types.

• Metagenomic next-generation sequencing (mNGS): An emerging technology that has revolutionized the diagnosis of infectious diseases. mNGS can detect B. henselae DNA in clinical samples without requiring prior knowledge of the pathogen, making it particularly useful for atypical presentations [22][30].

The Cornell Feline Health Center recommends PCR testing of blood or tissue samples as the preferred diagnostic method for active infection in cats.

6. Clinical Manifestations in Humans

6.1 Classic (Typical) CSD

The classic presentation of CSD in immunocompetent individuals follows a characteristic timeline:

Incubation period: 3 to 14 days after the scratch or bite.

Primary lesion: A small papule or pustule develops at the site of inoculation, typically on the arm, hand, face, or leg. This lesion may be mistaken for an insect bite and often resolves spontaneously within a few days.

Regional lymphadenopathy: 1 to 3 weeks after the scratch, the lymph node(s) draining the inoculation site become enlarged, tender, and sometimes fluctuant. The axillary lymph nodes are most commonly affected (reflecting the frequency of scratches on the upper extremities), followed by cervical, epitrochlear, and inguinal nodes [2]. The lymphadenopathy typically resolves over 2 to 4 months but can persist for longer.

Systemic symptoms: Low-grade fever, malaise, headache, and loss of appetite may accompany the lymphadenopathy.

A classic case report published in the New England Journal of Medicine illustrated the typical presentation with regional lymphadenopathy following a cat scratch [6].

6.2 Atypical CSD

Atypical presentations occur in approximately 5-20% of cases and can affect virtually any organ system. These presentations are more common in immunocompromised individuals but can also occur in immunocompetent patients.

6.2.1 Ocular Manifestations

Ocular CSD is one of the most common atypical presentations and can cause significant visual morbidity.

• Parinaud oculoglandular syndrome: Unilateral conjunctivitis with ipsilateral preauricular lymphadenopathy. This occurs when the inoculation site is the conjunctiva.

• Neuroretinitis: Inflammation of the optic nerve and retina, presenting with sudden vision loss, optic disc swelling, and macular star formation. A case report by Koga et al. (2026) described severe optic neuroretinitis and vitreous hemorrhage in a pediatric patient with irreversible visual impairment [15].

• Panuveitis: Severe inflammation of the entire uveal tract. Two recent case reports highlighted severe panuveitis as an uncommon presentation of CSD [20][21].

• Central retinal artery occlusion: A rare but devastating complication. Rao et al. (2026) reported a case of pediatric central retinal artery occlusion associated with B. henselae infection, demonstrating that CSD can cause vision-threatening vascular occlusions [1].

• Choroidal granuloma with serous retinal detachment: An atypical presentation that can occur even without known feline exposure, as described by Peng et al. (2026) [23].

6.2.2 Neurologic Manifestations

Neurologic involvement is a well-recognized but underdiagnosed complication of CSD.

• Encephalitis: CSD encephalitis is more common than previously recognized. A recent study by Yakubovsky et al. (2026) provided new insights into the rate, clinical features, and long-term outcomes of CSD encephalitis, finding that it can cause significant morbidity and that recovery may be incomplete in some cases [38].

• Meningitis: Subacute meningitis caused by B. henselae is under-recognized. Yakubovsky et al. (2026) emphasized that CSD should be considered in the differential diagnosis of subacute meningitis, especially in patients with cat exposure [25]. A case of B. henselae meningitis characterized by bone marrow hemophagocytosis has also been reported [13].

• Cranial nerve neuropathies: A rare manifestation involving single or multiple cranial nerves. Yakubovsky et al. (2026) described a series of patients with cranial nerve neuropathies due to CSD, including facial nerve palsy and hearing loss [35].

• Acute hearing loss: A case report from Israel documented CSD associated with acute sensorineural hearing loss, expanding the spectrum of neurologic complications [7].

• Peripheral neurological involvement: Arabeyre et al. (2026) reported peripheral neurological involvement in an immunocompetent adolescent, including radiculopathy and peripheral neuropathy [14].

6.2.3 Cardiovascular Manifestations

Bartonella species are important causes of culture-negative endocarditis.

• Infective endocarditis: B. henselae can cause both native and prosthetic valve endocarditis. A case report described prosthetic valve endocarditis with discordant ANCA positivity, highlighting the diagnostic challenge of distinguishing CSD from autoimmune vasculitis [12]. Another case documented tricuspid valve endocarditis presenting as fever of unknown origin [31].

• Myocarditis and heart failure: Braeckeveldt et al. (2026) reported a case of CSD progressing to heart failure in a young patient, demonstrating that Bartonella infection can have severe cardiac consequences [37].

• Multisystemic thrombo-inflammatory syndrome: A recent report described a multisystemic thrombo-inflammatory syndrome in an immunocompetent adult, including venous thromboembolism and systemic inflammation [17].

6.2.4 Renal Manifestations

Renal involvement in CSD is increasingly recognized.

• Glomerulonephritis: B. henselae can cause immune complex-mediated glomerulonephritis, which may mimic autoimmune disease. Pierson et al. (2026) reported successful treatment of crescentic glomerulonephritis in a renal transplant recipient [10]. Debyser et al. (2026) described disseminated bartonellosis masquerading as autoimmune glomerulonephritis [28].

• ANCA-associated vasculitis mimic: The presence of ANCA positivity in CSD-associated glomerulonephritis can lead to misdiagnosis as ANCA vasculitis, with important treatment implications [12][28].

6.2.5 Musculoskeletal Manifestations

• Osteomyelitis: B. henselae can cause bone infections, particularly in children. Wu et al. (2026) reported a case of atypical CSD with bone and joint infection diagnosed through clinical metagenomics [36].

• Arthritis: Reactive arthritis or septic arthritis may occur.

6.2.6 Lymphatic and Mediastinal Manifestations

• Mediastinal lymphadenitis: A rare but serious presentation that can mimic malignancy and cause critical airway compression, especially in children. Lu et al. (2026) reported a case of B. henselae mediastinal lymphadenitis with airway compression [3].

• Axillary lymphadenopathy: The most common presentation, as described in a case report and literature review by Chen and Li (2026) [2].

• Femoral lymph node abscess: Treatment-resistant femoral lymph node abscess caused by CSD was confirmed by PCR in a recent case report [34].

6.2.7 Pulmonary Manifestations

• Granulomatous lung disease: B. henselae can cause bacterial granulomatous lung disease, which must be differentiated from fungal, mycobacterial, and other causes. Giusto et al. (2026) reviewed the radiological findings and differential diagnosis of bacterial granulomatous lung diseases [8].

6.2.8 Hematologic Manifestations

• Hemophagocytic lymphohistiocytosis (HLH): Bone marrow hemophagocytosis has been reported in association with CSD meningitis [13].

• Thrombo-inflammatory syndrome: As noted above, a multisystemic thrombo-inflammatory syndrome including coagulopathy has been described [17].

6.2.9 Disseminated Disease in Immunocompromised Patients

Immunocompromised individuals are at highest risk for severe, disseminated disease.

• Organ transplant recipients: Sobczynska et al. (2026) reported disseminated CSD in a kidney transplant recipient [32]. Pierson et al. (2026) described crescentic glomerulonephritis in a renal transplant patient [10].

• Hematologic malignancies: Luan et al. (2026) reported CSD diagnosed via next-generation sequencing in a young patient with chronic lymphocytic leukemia on zanubrutinib therapy [29].

• HIV/AIDS: Disseminated bartonellosis, including bacillary angiomatosis and peliosis hepatis, is a well-known complication in HIV-infected patients.

6.3 CSD as a "Great Mimicker"

Systemic CSD in immunocompetent adults has been described as "another great mimicker" due to its ability to present with diverse symptoms that can mimic malignancy, autoimmune disease, and other infectious processes [19]. The diagnosis should be considered in any patient with unexplained fever, lymphadenopathy, and cat exposure, especially when initial workup for more common conditions is negative.

7. Diagnosis of CSD in Humans

7.1 Clinical Diagnosis

The diagnosis of CSD is often made clinically based on:

1. History of cat contact (especially kittens or flea-infested cats)
2. Presence of a primary inoculation lesion (papule or pustule)
3. Regional lymphadenopathy
4. Compatible systemic symptoms
5. Exclusion of other causes of lymphadenopathy

However, atypical presentations without obvious lymphadenopathy or cat exposure are common and require laboratory confirmation.

7.2 Laboratory Diagnosis

7.2.1 Serology

Indirect immunofluorescence antibody (IFA) testing for B. henselae IgM and IgG is the most widely available serologic method. A four-fold rise in IgG titers between acute and convalescent samples, or a single high IgG titer (greater than or equal to 1:256), supports the diagnosis. IgM antibodies indicate recent infection but are not always present.

7.2.2 Polymerase Chain Reaction (PCR)

PCR detection of B. henselae DNA in lymph node tissue, pus, blood, or cerebrospinal fluid is highly sensitive and specific. PCR is particularly useful for confirming atypical cases and for differentiating CSD from other causes of lymphadenopathy [34].

7.2.3 Metagenomic Next-Generation Sequencing (mNGS)

mNGS has emerged as a powerful diagnostic tool for CSD, especially in cases with atypical presentations or when conventional testing is negative. Yue et al. (2026) demonstrated the utility of mNGS for diagnosing CSD [22]. Multiple recent case reports have confirmed the value of mNGS in identifying B. henselae in challenging cases, including bone and joint infections [36], meningitis [25], and disease in immunocompromised patients [29]. The retrospective analysis by Lai et al. (2025) of mNGS-confirmed cases in children from southwestern China provided valuable epidemiological data [30].

7.2.4 Histopathology

Lymph node biopsy shows characteristic histologic features, including granulomatous inflammation with stellate microabscesses surrounded by palisading histiocytes. Warthin-Starry silver stain may demonstrate the bacilli, though sensitivity is low.

7.2.5 Culture

Isolation of B. henselae from clinical specimens is definitive but technically challenging and slow. Culture is rarely used for routine diagnosis but may be attempted in research settings or when antimicrobial susceptibility testing is needed.

7.3 Differential Diagnosis

The differential diagnosis for CSD includes:

• Infectious lymphadenitis: Staphylococcal, streptococcal, mycobacterial (including tuberculosis and atypical mycobacteria), tularemia, brucellosis, toxoplasmosis, Epstein-Barr virus, cytomegalovirus, HIV
• Malignancy: Lymphoma, leukemia, metastatic carcinoma
• Autoimmune disease: Systemic lupus erythematosus, sarcoidosis, ANCA vasculitis
• Other: Kikuchi disease, Kawasaki disease, drug reactions

The recent case of atypical invasive Chlamydia trachomatis mimicking lymphogranuloma venereum [27] serves as a reminder that other pathogens can produce similar clinical pictures.

8. Treatment and Management

8.1 Treatment in Cats

Treatment of Bartonella infection in cats remains controversial. Because most cats are asymptomatic carriers, and because antibiotic therapy does not reliably clear the bacteremia, routine treatment of healthy cats is not recommended by most veterinary authorities.

When treatment is considered:

• Cats with clinical bartonellosis (fever, lymphadenopathy, uveitis, etc.)
• Cats in households with immunocompromised humans
• Cats before immunosuppressive therapy

Antibiotic options:

• Doxycycline: 5-10 mg/kg orally every 12 hours for 4-6 weeks. This is the most commonly recommended antibiotic.
• Azithromycin: 5-10 mg/kg orally every 24 hours for 3-5 days, then every 48 hours for several weeks.
• Fluoroquinolones: Enrofloxacin or marbofloxacin may be used but with caution due to potential side effects.

Important caveat: No antibiotic regimen reliably eliminates B. henselae bacteremia in cats. A study by Olsen and Embers (2026) demonstrated that combination antibiotic therapy is required to eliminate B. henselae in multiple microenvironments, suggesting that single-agent therapy may be insufficient [16].

Flea control: This is the cornerstone of management. Eliminating fleas from the cat and the environment reduces the risk of reinfection and transmission.

8.2 Treatment in Humans

8.2.1 Immunocompetent Patients with Mild Disease

For typical, uncomplicated CSD in immunocompetent patients, treatment is primarily supportive. The disease is self-limiting, and lymphadenopathy resolves spontaneously over 2-4 months. Symptomatic management includes:

• Analgesics for pain
• Warm compresses to tender lymph nodes
• Needle aspiration of fluctuant lymph nodes for symptomatic relief (incision and drainage is avoided due to risk of fistula formation)

8.2.2 Immunocompetent Patients with Moderate to Severe Disease

Antibiotic therapy is indicated for patients with:

• Severe or painful lymphadenopathy
• Extranodal disease (atypical CSD)
• Prolonged symptoms (more than 2-3 months)

Recommended antibiotics:

• Azithromycin: 500 mg orally on day 1, then 250 mg daily for 4-5 days. This is the only antibiotic studied in a randomized controlled trial for CSD and was shown to accelerate resolution of lymphadenopathy.
• Doxycycline: 100 mg orally twice daily for 5-7 days (or longer for severe disease).
• Rifampin: 300 mg orally twice daily, often used in combination with doxycycline for severe disease.
• Ciprofloxacin: 500-750 mg orally twice daily (less preferred due to resistance concerns).
• Trimethoprim-sulfamethoxazole: Alternative option.

8.2.3 Severe or Disseminated Disease

For patients with endocarditis, encephalitis, neuroretinitis, or other severe manifestations, combination therapy with doxycycline plus rifampin or an aminoglycoside is recommended. Treatment duration is typically 4-6 weeks or longer, depending on clinical response.

Endocarditis: Combination therapy with doxycycline plus gentamicin (or another aminoglycoside) for at least 2 weeks, followed by doxycycline alone for 4-6 weeks. Valve replacement may be necessary in cases with significant valvular destruction [31][37].

Neuroretinitis: Doxycycline plus rifampin for 4-6 weeks. Despite treatment, some patients experience permanent visual impairment [15].

Encephalitis: Doxycycline plus rifampin for 4-6 weeks. Long-term outcomes may include persistent neurologic deficits [38].

8.2.4 Immunocompromised Patients

Immunocompromised patients require aggressive, prolonged antibiotic therapy. Doxycycline plus rifampin or an aminoglycoside for 4-6 months or longer is recommended. Lifelong suppressive therapy may be needed in some cases, particularly in HIV/AIDS patients with advanced immunosuppression.

8.2.5 Jarisch-Herxheimer Reaction

A Jarisch-Herxheimer reaction (an acute febrile reaction with flu-like symptoms) can occur following initiation of doxycycline therapy in CSD patients. Guri et al. (2025) reported this reaction in an adolescent with CSD, highlighting the need for clinician awareness [40].

8.3 Surgical Management

Surgical intervention is rarely needed but may be considered for:

• Diagnostic lymph node biopsy when malignancy is suspected
• Drainage of large, painful, fluctuant lymph nodes (needle aspiration preferred)
• Debridement of complicated wounds
• Valve replacement for endocarditis

9. Prevention and Public Health

9.1 Flea Control in Cats

Flea control is the single most effective preventive measure for CSD. The AVMA, AAHA, CVMA, and FVE all recommend year-round flea prevention for all cats, regardless of lifestyle.

Available flea control products:

• Topical spot-ons: Fipronil, selamectin, imidacloprid, dinotefuran
• Oral medications: Fluralaner, afoxolaner, sarolaner, lotilaner, nitenpyram
• Collars: Flumethrin/imidacloprid collars
• Environmental control: Vacuuming, washing bedding, using insect growth regulators

9.2 Reducing Zoonotic Transmission

Pet owners, especially those with immunocompromised household members, should be educated about:

1. Avoiding rough play with cats: Especially kittens, which are more likely to scratch and bite.
2. Washing scratches and bites immediately: Thoroughly clean any cat scratch or bite with soap and running water.
3. Not allowing cats to lick open wounds: Cover cuts and scrapes.
4. Keeping cats indoors: Reduces exposure to fleas and other vectors.
5. Declawing: The AVMA opposes declawing as a routine procedure and does not recommend it for CSD prevention. Alternatives include nail caps and regular nail trimming.
6. Hand hygiene: Wash hands after handling cats, especially kittens.

9.3 Special Considerations for Immunocompromised Individuals

Immunocompromised individuals (organ transplant recipients, HIV/AIDS patients, those on immunosuppressive therapy, pregnant women) should:

• Avoid adopting kittens under 1 year of age
• Avoid stray or shelter cats with unknown health history
• Delegate cat care tasks (litter box cleaning, flea treatment) to other household members
• Maintain rigorous flea control
• Seek prompt medical evaluation for any cat scratch or bite

9.4 Veterinary Personnel Precautions

Veterinary professionals are at increased risk for CSD due to frequent contact with cats and potential needlestick injuries. Precautions include:

• Wearing gloves when handling cats with suspected bartonellosis
• Using proper needle disposal techniques
• Seeking prompt medical evaluation for cat scratches, bites, or needlestick injuries
• Considering pre-exposure or post-exposure prophylaxis for high-risk exposures

9.5 Vaccine Development

There is currently no licensed vaccine for CSD in humans or cats. However, promising research is underway. Seflekci et al. (2026) designed and computationally evaluated a cross-protective multi-epitope vaccine candidate against B. henselae and B. clarridgeiae, the two main causative agents of CSD in humans [33]. If successful, such a vaccine could significantly reduce the burden of CSD.

10. Prognosis and Outcomes

10.1 Immunocompetent Patients

The prognosis for immunocompetent patients with typical CSD is excellent. Lymphadenopathy resolves spontaneously in 2-4 months, and complications are rare. Even in atypical cases, full recovery is the rule with appropriate antibiotic therapy.

10.2 Immunocompromised Patients

The prognosis is more guarded in immunocompromised patients. Disseminated disease can be life-threatening, and relapses are common after discontinuation of therapy. Long-term suppressive antibiotics may be required.

10.3 Long-Term Sequelae

While most patients recover fully, some may experience long-term sequelae:

• Visual impairment: Permanent vision loss can occur following neuroretinitis or central retinal artery occlusion [1][15].
• Neurologic deficits: Persistent cognitive impairment, cranial nerve palsies, or hearing loss may follow encephalitis or meningitis [7][35][38].
• Cardiac damage: Valvular damage from endocarditis may require long-term cardiac monitoring or valve replacement [37].
• Renal impairment: Glomerulonephritis may lead to chronic kidney disease in some cases [10][28].

11. Emerging Research and Future Directions

11.1 Improved Diagnostics

Metagenomic next-generation sequencing (mNGS) is revolutionizing the diagnosis of CSD, particularly for atypical presentations. As this technology becomes more widely available and affordable, it is likely to become a first-line diagnostic tool for complex infectious diseases [22][30].

11.2 Antimicrobial Resistance

While B. henselae has traditionally been susceptible to many antibiotics, emerging resistance is a concern. Olsen and Embers (2026) demonstrated that combination antibiotic therapy is required to eliminate B. henselae in multiple microenvironments, suggesting that monotherapy may select for resistant subpopulations [16]. Ongoing surveillance of antimicrobial susceptibility patterns is needed.

11.3 Vaccine Development

The computational design of a multi-epitope vaccine against B. henselae and B. clarridgeiae represents a significant step forward [33]. If preclinical and clinical trials are successful, a vaccine could be available for humans or cats in the coming years.

11.4 Understanding Host-Pathogen Interactions

Research into the genetic determinants of susceptibility and resistance to Bartonella infection in cats, including the role of blood type [11], may lead to new strategies for preventing infection in the reservoir host.

11.5 Alternative Vectors and Reservoirs

The detection of B. henselae DNA in triatomine bugs and ducks [9] raises questions about the full range of vectors and reservoirs for this pathogen. Further research is needed to determine the epidemiological significance of these findings.

12. Frequently Asked Questions (FAQ)

12.1 Can I get cat scratch disease from a healthy-looking cat?

Yes. Most cats infected with B. henselae show no signs of illness. Healthy-appearing cats, especially kittens, can carry the bacteria and transmit it to humans. Flea control is the most important preventive measure.

12.2 How long does cat scratch disease last in humans?

In typical cases, lymphadenopathy resolves spontaneously over 2 to 4 months. Antibiotic therapy can accelerate recovery. Atypical cases may require longer treatment and have variable recovery times depending on the organs involved.

12.3 Can cat scratch disease be fatal?

Fatalities are extremely rare in immunocompetent individuals. However, severe complications such as endocarditis, encephalitis, and disseminated disease can be life-threatening, particularly in immunocompromised patients.

12.4 Should I test my cat for Bartonella?

Routine testing of healthy cats is not recommended by most veterinary authorities. Testing may be considered in cats with compatible clinical signs or in households with immunocompromised individuals. However, a negative test does not rule out infection, and a positive test does not necessarily indicate active disease.

12.5 Can my cat be treated for Bartonella?

Treatment is not routinely recommended for healthy cats. Antibiotics may be considered for cats with clinical bartonellosis or in specific circumstances (e